Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • inetquirk inetquirk Dec 1, 2012 1:06 PM Flag

    Exceptional review

    RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an Outperform rating on Sunesis shares and raised his price target to $10 a share.

      RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.

      This review establishes an opinion of: MARKET OUTPERFORM price target $20

      Investors will probably agree with this review using their due diligence/fact checking.

      Respectfully,
      Inetquirk

    • Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an "Outperform" rating on Sunesis shares and raised his price target to $10 a share.

    • This review establishes an opinion of: MARKET OUTPERFORM price target $20

      Investors will probably agree with this review using their due diligence/fact checking.

      Respectfully,
      Inetquirk

 
SNSS
2.69+0.04(+1.51%)Apr 24 4:00 PMEDT